Clinical Trials Browser

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms, Neoplastic Cells, Circulating, Triple Negative Breast Neoplasms

Triple Negative Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Triple Negative Breast Neoplasms

Triple Negative Breast Neoplasms

Triple Negative Breast Neoplasms

Triple Negative Breast Neoplasms

Pathologic Complete Response, Breast Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Triple Negative Breast Neoplasms

Triple Negative Breast Neoplasms

Triple Negative Breast Neoplasms

Triple Negative Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Triple Negative Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Triple Negative Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Triple Negative Breast Neoplasms

Triple Negative Breast Neoplasms

Kenny-Caffey syndrome, Type 1, Breast Neoplasms, Triple Negative Breast Neoplasms

Triple Negative Breast Neoplasms

Triple Negative Breast Neoplasms

Triple Negative Breast Neoplasms

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Triple Negative Breast Neoplasms

Clinical Trials

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

TARMAC

NeoSACT

MK-5890-003

TARMAC

neoMono

Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC

MK-3475-522

NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC

Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer

FASCINATE-N

A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chemotherapy Versus Anthracycline/Taxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer

Evaluating Bemotuzumab to Improve the Efficacy of Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer (TNBC)

CITRINE

Non-Inferiority Study on MRNA-lncRNA Model in Low-Risk Triple-Negative Breast Cancer Patients

B-IMMUNE

NeoTENNIS

KEYPARTNER

TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature

Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer

HIFU

NIB

Neoadjuvant Study of Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer (TNBC)

Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy

GeparOla

to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC)

SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breast Cancer

The Trial Comparing Dose-dense AC-T With TP as Adjuvant Therapy for TNBC With Homologous Recombination Repair Deficiency

Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer

The Trial Comparing Dose-dense AC-T With PC as Adjuvant Therapy for TNBC

Comparison Study of Neoadjuvant Paclitaxel Plus Carboplatin/Epirubicin Treatment in Triple-negative Breast Cancer